Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

HORSHOLM, Denmark, July 14 /PRNewswire/ -- The Board of Directors of Santaris Pharma has approved the Interim Report for the period 1 January to 30 June 2009.

    - The loss after tax realised in the 2nd quarter of 2009 was
      21,6m DKK (2,9m EUR) compared to 29,8m DKK (4,0m EUR) in the 2nd
      quarter of 2008.

    - As at June 30, 2009 the capital resources totalled 175,4m
      DKK (23,6m EUR).

    - In Q2 the SPC3649 compound targeting hepatitis C finalized a
      single dose First/In/Man study with encouraging results and a multiple
      ascending dose study in healthy volunteers is scheduled to commence in
      Q3 2009.

    - Santaris Pharma's new lead candidate SPC4955 targeting
      apoliproteinB, the major cholesterol carrying protein in the blood, has
      been selected for preclinical trials.

    - Lead candidates targeting PCSK9, which is known to play a
      critical role in regulating cholesterol levels, have been selected for
      pharmacological studies.

    - The Collaboration with the Company's 3rd partner, Wyeth, was
      initiated during the first months of 2009 and is progressing according
      to the plan.


    (Logo:http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

During the first half of 2009 Santaris Pharma continued to make satisfactory progress in its research and development programs within miRNA, metabolic disorders and infectious diseases. Key milestones achieved and other events during the quarter are summarized below.

Development

SPC3649-HCV

SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in cholesterol metabolism and in hepatitis virus replication in the liver. In April 2009, Santaris Pharma completed a Phase I First-in-Man single dose study of SPC3649 with 60 healthy volunteers and t
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Three Lawrence Livermore researchers have ... Production R&D Award for their research in ... sunlight. , Shared with collaborators from the National ... Nevada, Las Vegas (UNLV), the award recognizes the ... solar-hydrogen production and corrosion processes. , These models ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Best Sanitizers, ... for the food processing industry, is asking industry professionals ... side comparison of the E2 soap they’re currently using ... Foam Soap . Hand hygiene is critical to ... food processing environment. Six key criteria are identified to ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... SAN FRANCISCO, September 22, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Sept. 22 RF Technologies®, a leading provider of ... announces the hiring of Mark Harwood as company President. ... Inc. and former President and CEO of Arjo, Inc. ... of success in the high-tech, healthcare and medical device ...
... Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ... Scientific Officer, Robert Lanza, MD, and Kwang-Soo Kim, PhD, ... National Institutes of Health (NIH) Director,s Opportunity Award for ... Better Treatments" under the American Recovery & Reinvestment Act ...
Cached Biology Technology:Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 2Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 3Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 4Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 5Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 6Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 7Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 8Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 9Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients 10RF Technologies® Names Mark Harwood New President 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 2Drs. Robert Lanza and Kwang-Soo Kim Win Prestigious NIH Director's Award 3
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
(Date:8/29/2014)... A leading U.S. Ebola researcher from the University of Texas ... a blend of three monoclonal antibodies can completely protect monkeys ... days after infection, at a time when the disease is ... written an editorial for Nature discussing advances in ... Marburg virus are among the most deadly of pathogens, with ...
(Date:8/29/2014)... Dartmouth researchers explored the type and number of connections ... assortativity plays on robustness in a study published in ... study found that the assortativity signature contributes to a ... seems that varying the out-out assortativity of TFN models ... of the other three types of assortativity," said Dov ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2
... represent a major and unsolved health issue worldwide. The ... disease, highlighting the urgent need for better knowledge of ... of researchers led by scientists at the Salk Institute ... study kidney diseases, opening new avenues for the future ...
... University of Illinois anthropology professor Ripan Malhi ... first came to the Americas and what happened to them once ... at the meeting, " Ancient DNA: The First Three Decades ," ... Malhi, an affiliate of the Institute for Genomic Biology ...
... cells offer the opportunity to harvest abundant, renewable energy. Although ... spectrum, most solar energy is in the infrared. There is ... are efficient in the infrared but waste much of the ... part of the spectrum. When a photon is absorbed ...
Cached Biology News:Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 2Salk scientists for the first time generate 'mini-kidney' structures from human stem cells 3Ancient, modern DNA tell story of first humans in the Americas 22 for 1 in solar power 2
... Ideal for staining westerns and includes stickers ... Pour spouts in each corner facilitate pouring ... be used for identification. Lid is designed ... for staining several gels simultaneously. Lid also ...
ID clarifier: non-treated with lid...
... Staccato Series of systems provide fast and reliable scalable ... drug development laboratories. Staccato systems are available in three ... Systems Series. ... All Staccato ...
... Staccato Custom Series Systems provide ... drug discovery, genomics, proteomics and drug ... built specifically to customer specifications, providing ... individual needs. Staccato Custom Systems ...
Biology Products: